Consortium Gram News Today

The European-funded GNA NOW Consortium and Nosopharm, a biotechnology company exploring unconventional sources of antibiotics with potential in the fight against antimicrobial resistance, have announced a milestone development following completion and positive results of toxicology studies for a first-in-class antibiotic for the treatment of multidrug-resistant infections. Click to read more...

An important milestone has been reached for the GNA NOW Consortium with the completion of the GLP toxicology studies for the NOSO-502 program. The results allow for the further development of the program to Phase 1 Utrecht, the Netherlands, and Lyon, France, 8 June 2022 – Nosopharm, a biotechnology company specializ...